Ovarian Cancer

The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Encouraging interim data were reported from the ongoing phase I clinical trial of STRO-002 regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer.

The findings presented in this study suggest the breastfeeding may be a potentially modifiable factor that could lower risk of ovarian cancer independent of pregnancy alone.

PARP inhibitors take center stage at the Society of Gynecologic Oncology’s 25th Annual Winter Meeting

The FDA accepted a supplemental new drug application for niraparib, treating women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status, based on data from the PRIMA study.

A new tool, in combination with those already existing, could distinguish between patients with malignant and benign ovarian masses, as well as those with a benign ovarian mass and normal ovaries.

The O-RADS MRI tool could potentially reduce unnecessary or over-extensive surgery in patients with various types of ovarian cancer.

This large meta-analysis was found to support the GCIG Fifth Ovarian Cancer Consensus statement that OS is the preferred primary end point.

A recent study suggested the activation of apelin/APJ signaling decreased efficacy in VEGF treatment, while bevacizumab decreased disease-free survival rates with increased expression of apelin in patients of ovarian cancer.

The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone.

Largest analysis of data to date shows no link between use of talc powder and rate of ovarian cancer incidence

A study showed that first-line treatment for epithelial ovarian cancer using weekly dose-dense chemotherapy did not improve progression-free survival, compared with 3-weekly chemotherapy, in European women.

Patients recently diagnosed with ovarian cancer indicated that they would accept a moderately higher risk of complication and surgical mortality in exchange for higher overall survival.

The updated and expanded NCCN guidelines broaden the testing criteria, while clarifying who should be tested for genetic mutations.

Researchers compared primary high grade serous ovarian carcinoma tumors and their matched metastasis, showing evidence of separating the 2 sample types and potentially predicting patient survival.

Research suggests that oncogene S100A10 may play a definitive role in the progression of ovarian cancer and its expression levels may affect sensitivity to carboplatin.

Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.

The approval comes one day after the FDA approved niraparib for the same subset of ovarian cancer.

Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.

A new study found a link between posttraumatic stress disorder and ovarian cancer.

The clear cell histologic subtype of stage I ovarian cancer is associated with a disproportionately high risk for capsule rupture during surgery compared with other histologies.

Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.

Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.

Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.

The results of the first therapy to use a PARP inhibitor with chemotherapy for patients with ovarian cancer were presented at ESMO Congress 2019.